{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-26-000550","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.681628+00:00","generated_at":"2026-05-15T08:47:22.732112+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Vivani Medical reports FY2025 net loss $26.6M; advances semaglutide implant NPM-139 towards Phase 1","bullets":["FY2025 net loss $26.6M vs $23.5M in FY2024; R&D expenses $18.1M up 15% YoY.","Cash $16.2M as of Dec 31, 2025; raised $41.5M gross from financings; funds ops into mid-2027.","Successful LIBERATE-1 first-in-human study; preclinical data shows >20% sham-adjusted weight loss for full year with single semaglutide implant.","Phase 1 study of NPM-139 (semaglutide implant) for chronic weight management expected mid-2026 with results by end of 2026.","Exploring spin-off or IPO of subsidiary Cortigent (neuromodulation assets)."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-26-000550","json":"https://secwatch.observer/filing/0001753926-26-000550.json","markdown":"https://secwatch.observer/filing/0001753926-26-000550.md","text":"https://secwatch.observer/filing/0001753926-26-000550.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392626000550/0001753926-26-000550-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392626000550/vani-20260326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:47:22.732112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}